ALTERITY THERAPEUTICS LIMITED - Announcements

Market Cap $31.47M Add to my watchlist

Healthcare Biotechnology

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company.... Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company’s lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson’s disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.More

Announcements

Filter Results

All Price Sensitive Only

ATH	Company update on Annual Report 2020	PRICE SENSITIVE	09/09/20	177.51KB	Share
ATH	Results of Meeting		03/09/20	165.83KB	Share
ATH	Preliminary Final Report	PRICE SENSITIVE	31/08/20	513.84KB	Share
ATH	Change in substantial holding		17/08/20	1.87MB	Share
ATH	New data independently confirms safety profile of ATH434	PRICE SENSITIVE	04/08/20	229.39KB	Share
ATH	Notice of General Meeting		03/08/20	676.89KB	Share
ATH	Appendix 4C and Quarterly Cash Flow Report	PRICE SENSITIVE	30/07/20	375.42KB	Share
ATH	Change in substantial holding		15/07/20	327.92KB	Share
ATH	Change in substantial holding		13/07/20	1.9MB	Share
ATH	Change in substantial holding		09/07/20	1.93MB	Share
ATH	Change in substantial holding		08/07/20	2.33MB	Share
ATH	Change in substantial holding		07/07/20	1016.9KB	Share
ATH	Change in substantial holding		06/07/20	329.86KB	Share
ATH	Appendix 2A and Section 708A(5) Cleansing Notice		02/07/20	378.75KB	Share
ATH	Proposed issue of Securities - ATH		01/07/20	24.51KB	Share
ATH	Response to ASX Price Query	PRICE SENSITIVE	01/07/20	1003.48KB	Share
ATH	Pause in Trading	PRICE SENSITIVE	01/07/20	115.98KB	Share
ATH	Meeting with US FDA provides development path for ATH434	PRICE SENSITIVE	30/06/20	210.21KB	Share
ATH	Change in substantial holding		09/06/20	331.57KB	Share
ATH	Change in substantial holding		28/05/20	167.04KB	Share
ATH	Change in substantial holding (BMYMC)		27/05/20	283.44KB	Share
ATH	Change in substantial holding		27/05/20	283.44KB	Share
ATH	Appendix 2A and Section 708A(5) Cleansing Notice		25/05/20	385.49KB	Share
ATH	Proposed issue of Securities - ATH		22/05/20	24.88KB	Share
ATH	Presentation on ATH434 to American Academy of Neurology	PRICE SENSITIVE	21/05/20	203.75KB	Share
ATH	Appendix 4C and Quarterly Update	PRICE SENSITIVE	30/04/20	345.52KB	Share
ATH	NASDAQ Temporary Relief	PRICE SENSITIVE	22/04/20	193.8KB	Share
ATH	Appendix 2A and Section 708A(5) Cleansing		27/03/20	382.9KB	Share
ATH	Proposed issue of Securities - ATH		26/03/20	24.5KB	Share
ATH	Form 6K		28/02/20	232.43KB	Share
ATH	Half Yearly Report and Accounts	PRICE SENSITIVE	27/02/20	432.22KB	Share
ATH	NASDAQ Non-Compliance Notice Received	PRICE SENSITIVE	07/02/20	217.47KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/20	372.04KB	Share
ATH	Appendix 3B an 708A notice		17/01/20	343.39KB	Share
ATH	Alterity receives a $4.8 million R&D Tax Incentive Refund	PRICE SENSITIVE	15/01/20	150.88KB	Share
ATH	European Orphan Designation granted for PBT434 for MSA	PRICE SENSITIVE	14/01/20	154.13KB	Share
ATH	Upcoming Release of warrants from Voluntary Escrow		11/12/19	149.25KB	Share
ATH	AGM Results of Meeting		26/11/19	168.86KB	Share
ATH	AGM Presentation 2019	PRICE SENSITIVE	26/11/19	776.76KB	Share
ATH	Chairman's Address to Shareholders	PRICE SENSITIVE	26/11/19	155.78KB	Share
ATH	Appendix 3B		21/11/19	343.75KB	Share
ATH	Alterity AGM Investor Conference Call		20/11/19	258.87KB	Share
ATH	Lead drug candidate receives positive opinion from EMA	PRICE SENSITIVE	18/11/19	153.3KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	30/10/19	346.34KB	Share
ATH	Notice of Annual General Meeting/Proxy Form		25/10/19	1.16MB	Share
ATH	ATH presents PBT434 clinical data at the 2019 MDS Congress		24/09/19	220.04KB	Share
ATH	Alterity to Present at the Janney Healthcare Conference		09/09/19	234.13KB	Share
ATH	Annual Report 2019 and XBRL data filed with the SEC		02/09/19	162.2KB	Share
ATH	Form 20-F		02/09/19	827.7KB	Share
ATH	Appendix 4G & Corporate governance statement 2019		30/08/19	341.21KB	Share
ATH	Appendix 4E & Annual Report 2019	PRICE SENSITIVE	30/08/19	1.69MB	Share
ATH	Change in substantial holding		20/08/19	1005.26KB	Share
ATH	Upcoming Release of Shares from Voluntary Escrow		05/08/19	436.71KB	Share
ATH	Appendix 3B		01/08/19	383.32KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/19	373.15KB	Share
ATH	Successful Completion of Phase 1 Clinical Trial	PRICE SENSITIVE	29/07/19	203.92KB	Share
ATH	Ceasing to be a substantial holder - ATH		04/06/19	448.15KB	Share
ATH	Alterity Therapeutics presents to Finance News Network		04/06/19	1.2MB	Share
ATH	Prospectus filed pursuant to SEC Rule 424(b)(3)	PRICE SENSITIVE	23/05/19	441.28KB	Share
ATH	Upcoming Release of Shares from Escrow		20/05/19	207.91KB	Share
ATH	FORM F-3		14/05/19	857.19KB	Share
ATH	Alterity Therapeutics commences US investor meetings		13/05/19	210.36KB	Share
ATH	Form 603 Notice lodged by Bank of New York Mellon		08/05/19	211.29KB	Share
ATH	Becoming a substantial holder		08/05/19	2.23MB	Share
ATH	Alterity presents initial Phase 1 clinical trial data at AAN	PRICE SENSITIVE	06/05/19	720.93KB	Share
ATH	ATH presents at the American Academy of Neurology		03/05/19	246.45KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	17/04/19	160.57KB	Share
ATH	Initial Director's Interest Notice - DS		11/04/19	130.69KB	Share
ATH	Initial Director's Interest Notice - TE		11/04/19	130.81KB	Share
ATH	Final Director's Interest Notice - GM		11/04/19	133.58KB	Share
ATH	Final Director's Interest Notice - IS		11/04/19	133.57KB	Share
ATH	Becoming a substantial holder - Alterity		11/04/19	720.12KB	Share
ATH	Investor Presentation - April 2019		10/04/19	2.16MB	Share
ATH	Alterity Therapeutics Launches to Asian Investors		10/04/19	217.11KB	Share
ATH	Becoming a substantial holder		10/04/19	1.36MB	Share
ATH	Change of Company Name		08/04/19	204.2KB	Share
ATH	Completion of investment by Life Biosciences & capital raise		08/04/19	556.71KB	Share
ATH	Results of Meeting		05/04/19	198.08KB	Share
ATH	Prana Biotechnology EGM and Conference Call Facility		27/03/19	155.43KB	Share
ATH	Appendix 3B		21/03/19	345.9KB	Share
ATH	Prana receives A$3.3 million R&D Tax Incentive Refund	PRICE SENSITIVE	18/03/19	214.95KB	Share
ATH	Notice of General Meeting/Proxy Form		06/03/19	3.64MB	Share
ATH	Form 6-K		01/03/19	408.94KB	Share
ATH	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/19	217.91KB	Share
ATH	Appendix 3B & Cleansing notice		05/02/19	394.31KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/19	249.91KB	Share
ATH	Orphan Designation for PBT434 for treatment of MSA	PRICE SENSITIVE	31/01/19	134KB	Share
ATH	Ceasing to be a substantial holder from MUFG		09/01/19	165.29KB	Share
ATH	Ceasing to be a substantial holder from MS		09/01/19	259.84KB	Share
ATH	Becoming a substantial holder from MUFG		07/01/19	457.7KB	Share
ATH	Becoming a substantial holder from MS		07/01/19	540.47KB	Share
ATH	Investor presentation - Biotech Showcase		07/01/19	1.47MB	Share
ATH	Prana Presents at Biotech Showcase		07/01/19	676.1KB	Share
ATH	Appendix 3B & Section 708A notice		07/01/19	955.14KB	Share
ATH	Life Bioscience LLC leads strategic investment upto A$44.5M	PRICE SENSITIVE	28/12/18	235.93KB	Share
ATH	Trading Halt	PRICE SENSITIVE	24/12/18	458.83KB	Share
ATH	Form S-8		05/12/18	270.98KB	Share
ATH	Change of Director's Interest Notice - IS		16/11/18	466.56KB	Share
ATH	Appendix 3B		16/11/18	971.8KB	Share
ATH	Results of Meeting		16/11/18	185.84KB	Share

ATH Company update on Annual Report 2020
09/09/20	PRICE SENSITIVE	177.51KB	Share
ATH Results of Meeting
03/09/20		165.83KB	Share
ATH Preliminary Final Report
31/08/20	PRICE SENSITIVE	513.84KB	Share
ATH Change in substantial holding
17/08/20		1.87MB	Share
ATH New data independently confirms safety profile of ATH434
04/08/20	PRICE SENSITIVE	229.39KB	Share
ATH Notice of General Meeting
03/08/20		676.89KB	Share
ATH Appendix 4C and Quarterly Cash Flow Report
30/07/20	PRICE SENSITIVE	375.42KB	Share
ATH Change in substantial holding
15/07/20		327.92KB	Share
ATH Change in substantial holding
13/07/20		1.9MB	Share
ATH Change in substantial holding
09/07/20		1.93MB	Share
ATH Change in substantial holding
08/07/20		2.33MB	Share
ATH Change in substantial holding
07/07/20		1016.9KB	Share
ATH Change in substantial holding
06/07/20		329.86KB	Share
ATH Appendix 2A and Section 708A(5) Cleansing Notice
02/07/20		378.75KB	Share
ATH Proposed issue of Securities - ATH
01/07/20		24.51KB	Share
ATH Response to ASX Price Query
01/07/20	PRICE SENSITIVE	1003.48KB	Share
ATH Pause in Trading
01/07/20	PRICE SENSITIVE	115.98KB	Share
ATH Meeting with US FDA provides development path for ATH434
30/06/20	PRICE SENSITIVE	210.21KB	Share
ATH Change in substantial holding
09/06/20		331.57KB	Share
ATH Change in substantial holding
28/05/20		167.04KB	Share
ATH Change in substantial holding (BMYMC)
27/05/20		283.44KB	Share
ATH Change in substantial holding
27/05/20		283.44KB	Share
ATH Appendix 2A and Section 708A(5) Cleansing Notice
25/05/20		385.49KB	Share
ATH Proposed issue of Securities - ATH
22/05/20		24.88KB	Share
ATH Presentation on ATH434 to American Academy of Neurology
21/05/20	PRICE SENSITIVE	203.75KB	Share
ATH Appendix 4C and Quarterly Update
30/04/20	PRICE SENSITIVE	345.52KB	Share
ATH NASDAQ Temporary Relief
22/04/20	PRICE SENSITIVE	193.8KB	Share
ATH Appendix 2A and Section 708A(5) Cleansing
27/03/20		382.9KB	Share
ATH Proposed issue of Securities - ATH
26/03/20		24.5KB	Share
ATH Form 6K
28/02/20		232.43KB	Share
ATH Half Yearly Report and Accounts
27/02/20	PRICE SENSITIVE	432.22KB	Share
ATH NASDAQ Non-Compliance Notice Received
07/02/20	PRICE SENSITIVE	217.47KB	Share
ATH Appendix 4C - quarterly
31/01/20	PRICE SENSITIVE	372.04KB	Share
ATH Appendix 3B an 708A notice
17/01/20		343.39KB	Share
ATH Alterity receives a $4.8 million R&D Tax Incentive Refund
15/01/20	PRICE SENSITIVE	150.88KB	Share
ATH European Orphan Designation granted for PBT434 for MSA
14/01/20	PRICE SENSITIVE	154.13KB	Share
ATH Upcoming Release of warrants from Voluntary Escrow
11/12/19		149.25KB	Share
ATH AGM Results of Meeting
26/11/19		168.86KB	Share
ATH AGM Presentation 2019
26/11/19	PRICE SENSITIVE	776.76KB	Share
ATH Chairman's Address to Shareholders
26/11/19	PRICE SENSITIVE	155.78KB	Share
ATH Appendix 3B
21/11/19		343.75KB	Share
ATH Alterity AGM Investor Conference Call
20/11/19		258.87KB	Share
ATH Lead drug candidate receives positive opinion from EMA
18/11/19	PRICE SENSITIVE	153.3KB	Share
ATH Appendix 4C - quarterly
30/10/19	PRICE SENSITIVE	346.34KB	Share
ATH Notice of Annual General Meeting/Proxy Form
25/10/19		1.16MB	Share
ATH ATH presents PBT434 clinical data at the 2019 MDS Congress
24/09/19		220.04KB	Share
ATH Alterity to Present at the Janney Healthcare Conference
09/09/19		234.13KB	Share
ATH Annual Report 2019 and XBRL data filed with the SEC
02/09/19		162.2KB	Share
ATH Form 20-F
02/09/19		827.7KB	Share
ATH Appendix 4G & Corporate governance statement 2019
30/08/19		341.21KB	Share
ATH Appendix 4E & Annual Report 2019
30/08/19	PRICE SENSITIVE	1.69MB	Share
ATH Change in substantial holding
20/08/19		1005.26KB	Share
ATH Upcoming Release of Shares from Voluntary Escrow
05/08/19		436.71KB	Share
ATH Appendix 3B
01/08/19		383.32KB	Share
ATH Appendix 4C - quarterly
31/07/19	PRICE SENSITIVE	373.15KB	Share
ATH Successful Completion of Phase 1 Clinical Trial
29/07/19	PRICE SENSITIVE	203.92KB	Share
ATH Ceasing to be a substantial holder - ATH
04/06/19		448.15KB	Share
ATH Alterity Therapeutics presents to Finance News Network
04/06/19		1.2MB	Share
ATH Prospectus filed pursuant to SEC Rule 424(b)(3)
23/05/19	PRICE SENSITIVE	441.28KB	Share
ATH Upcoming Release of Shares from Escrow
20/05/19		207.91KB	Share
ATH FORM F-3
14/05/19		857.19KB	Share
ATH Alterity Therapeutics commences US investor meetings
13/05/19		210.36KB	Share
ATH Form 603 Notice lodged by Bank of New York Mellon
08/05/19		211.29KB	Share
ATH Becoming a substantial holder
08/05/19		2.23MB	Share
ATH Alterity presents initial Phase 1 clinical trial data at AAN
06/05/19	PRICE SENSITIVE	720.93KB	Share
ATH ATH presents at the American Academy of Neurology
03/05/19		246.45KB	Share
ATH Appendix 4C - quarterly
17/04/19	PRICE SENSITIVE	160.57KB	Share
ATH Initial Director's Interest Notice - DS
11/04/19		130.69KB	Share
ATH Initial Director's Interest Notice - TE
11/04/19		130.81KB	Share
ATH Final Director's Interest Notice - GM
11/04/19		133.58KB	Share
ATH Final Director's Interest Notice - IS
11/04/19		133.57KB	Share
ATH Becoming a substantial holder - Alterity
11/04/19		720.12KB	Share
ATH Investor Presentation - April 2019
10/04/19		2.16MB	Share
ATH Alterity Therapeutics Launches to Asian Investors
10/04/19		217.11KB	Share
ATH Becoming a substantial holder
10/04/19		1.36MB	Share
ATH Change of Company Name
08/04/19		204.2KB	Share
ATH Completion of investment by Life Biosciences & capital raise
08/04/19		556.71KB	Share
ATH Results of Meeting
05/04/19		198.08KB	Share
ATH Prana Biotechnology EGM and Conference Call Facility
27/03/19		155.43KB	Share
ATH Appendix 3B
21/03/19		345.9KB	Share
ATH Prana receives A$3.3 million R&D Tax Incentive Refund
18/03/19	PRICE SENSITIVE	214.95KB	Share
ATH Notice of General Meeting/Proxy Form
06/03/19		3.64MB	Share
ATH Form 6-K
01/03/19		408.94KB	Share
ATH Half Yearly Report and Accounts
28/02/19	PRICE SENSITIVE	217.91KB	Share
ATH Appendix 3B & Cleansing notice
05/02/19		394.31KB	Share
ATH Appendix 4C - quarterly
31/01/19	PRICE SENSITIVE	249.91KB	Share
ATH Orphan Designation for PBT434 for treatment of MSA
31/01/19	PRICE SENSITIVE	134KB	Share
ATH Ceasing to be a substantial holder from MUFG
09/01/19		165.29KB	Share
ATH Ceasing to be a substantial holder from MS
09/01/19		259.84KB	Share
ATH Becoming a substantial holder from MUFG
07/01/19		457.7KB	Share
ATH Becoming a substantial holder from MS
07/01/19		540.47KB	Share
ATH Investor presentation - Biotech Showcase
07/01/19		1.47MB	Share
ATH Prana Presents at Biotech Showcase
07/01/19		676.1KB	Share
ATH Appendix 3B & Section 708A notice
07/01/19		955.14KB	Share
ATH Life Bioscience LLC leads strategic investment upto A$44.5M
28/12/18	PRICE SENSITIVE	235.93KB	Share
ATH Trading Halt
24/12/18	PRICE SENSITIVE	458.83KB	Share
ATH Form S-8
05/12/18		270.98KB	Share
ATH Change of Director's Interest Notice - IS
16/11/18		466.56KB	Share
ATH Appendix 3B
16/11/18		971.8KB	Share
ATH Results of Meeting
16/11/18		185.84KB	Share

REFRESH

First 2 3 4 5 6

(20min delay)
Last 0.6¢		Change 0.000(0.00%)		Mkt cap ! $31.47M

Open	High	Low	Value	Volume
0.6¢	0.6¢	0.6¢	$9.573K	1.633M

Buyers (Bids)

No.	Vol.	Price($)
70	66663606	0.5¢

Sellers (Offers)

Price($)	Vol.	No.
0.6¢	12189391	9

View Market Depth

No.	Vol.	Price($)
70	66663606	0.005
53	59859382	0.004
49	47623315	0.003
17	33693014	0.002
12	93870101	0.001

Price($)	Vol.	No.
0.006	12189391	9
0.007	21612749	17
0.008	16761310	22
0.009	11788078	12
0.010	2540594	8

Last trade - 16.10pm 08/05/2024 (20 minute delay)


Last 0.6¢		Change 0.000 ( 0.00 %)
Open	High	Low	Volume
0.6¢	0.6¢	0.6¢	363313
Last updated 15.59pm 08/05/2024 ?

ATH (ASX) Chart

ALTERITY THERAPEUTICS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories